Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice.
about
Alpha-1-antitrypsin deficiencyChallenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene TherapyTargeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 MiceTherapeutic targeting of misfolding and conformational change in α1-antitrypsin deficiency.Two New Considerations for Improving the Diagnosis of α1-Antitrypsin Deficiency-Associated Liver DiseaseDisease Modification in Emphysema Related to Alpha-1 Antitrypsin Deficiency.Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases.Current and Emerging Treatments for Alpha-1 Antitrypsin Deficiency.Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.Using antisense technology to develop a novel therapy for α-1 antitrypsin deficient (AATD) liver disease and to model AATD lung disease.Knockdown of Z Mutant Alpha-1 Antitrypsin In Vivo Using Modified DNA Antisense Oligonucleotides.Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Approaches and Future Directions.Bone marrow stem cell therapy partially ameliorates pathological consequences in livers of mice expressing mutant human α1-antitrypsin.α1-Antitrypsin deficiency.Therapeutic Genome Editing With CRISPR/Cas9 in a Humanized Mouse Model Ameliorates α1-antitrypsin Deficiency Phenotype.Autophagy induced by exogenous bile acids is therapeutic in a model of α-1-AT deficiency liver disease.
P2860
Q26995192-BCE865EA-9214-43F6-BE55-27D12052B421Q28080450-85DA81B6-44F6-4A17-9AB3-6ADF73827AEEQ33752585-2960A414-4A62-49ED-9D9E-435FDCA3090EQ35214289-46248A54-900E-4C23-BFCE-FC1FD686944AQ35685102-0EE1A4E6-F824-48F7-BDDD-515EFD55E9D4Q38832928-ADF4EDED-89B5-451C-B2D2-B7E240A69F32Q41402538-1E52E066-10BE-4474-901F-15440246A14AQ41822847-FD615EB1-0373-41B3-A293-C40633D4B12EQ41846059-951C1DA9-B623-4B2B-935A-279008597697Q41894323-04887C8C-AE29-45AF-9D58-CF3EAA15CC67Q48018036-424DFDFC-DE86-4781-B978-B9327DF719CAQ49167837-56B5D865-D56B-48A4-A4E4-5C325B3FAF5FQ51215263-D3FD8324-03C6-474B-94E6-CFCD41E0B3E8Q51481224-13162DEB-83DC-4288-B6D7-6F2CE05066A1Q51736555-4CD2B10C-942E-497A-8B5D-592C327C27DAQ52873755-0DD86EC4-513B-4F35-919E-B9E807A9C63D
P2860
Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antisense oligonucleotide trea ...... related liver disease in mice.
@en
Antisense oligonucleotide trea ...... related liver disease in mice.
@nl
type
label
Antisense oligonucleotide trea ...... related liver disease in mice.
@en
Antisense oligonucleotide trea ...... related liver disease in mice.
@nl
prefLabel
Antisense oligonucleotide trea ...... related liver disease in mice.
@en
Antisense oligonucleotide trea ...... related liver disease in mice.
@nl
P2093
P2860
P356
P1476
Antisense oligonucleotide trea ...... -related liver disease in mice
@en
P2093
Andrew Watt
Brett P Monia
Chenguang Zhao
Danielle Gattis
Keith Blomenkamp
Mariam Aghajan
Michael L McCaleb
Sheri L Booten
Shuling Guo
P2860
P304
P356
10.1172/JCI67968
P407
P577
2013-12-20T00:00:00Z